Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group.
Study Goal
The researchers aimed to evaluate the efficacy of vitamin D supplementation in preventing fractures and falls, particularly in older adults and those at risk of deficiency.
Results Summary
The study found that high-dose vitamin D supplementation (2000-100,000 IU/month) did not prevent fractures or falls in vitamin D-replete individuals, but recommended 1000 IU daily for those at risk of deficiency.
Population
Older adults and individuals at increased risk of vitamin D deficiency.
Effective Dosage
200-2000 IU/day (recommended), 2000-100,000 IU/month (tested).
Duration
Not specified.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D supplementation | neutral | - | certain age groups | - | justify | #1 |
vitamin D supplementation | increase | circulating 25-hydroxyvitamin D (calcifediol) | older adults | at least 50 nmol/L | recommended doses vary | #2 |
oral vitamin D regimens | no change | prevention of fracture and falls | vitamin D-replete and healthy individuals | - | failed to detect any efficacy | #3 |
vitamin D | neutral | - | - | - | well-recognized major musculoskeletal disorders associated with | #4 |
vitamin D | neutral | fracture and fall risks | - | - | possible biphasic effects | #5 |
1000 IU daily | neutral | - | patients at increased risk of vitamin D deficiency | - | should be recommended | #6 |
vitamin D loading dose | increase | early 25-hydroxyvitamin D therapeutic level | patients | - | possibly benefitting from | #7 |
calcifediol administration | neutral | - | patients | - | possibly benefitting from | #8 |
Vitamin D is a key component for optimal growth and for calcium-phosphate homeostasis. Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation in certain age groups. In older adults, recommended doses for vitamin D supplementation vary between 200 and 2000 IU/day, to achieve a goal of circulating 25-hydroxyvitamin D (calcifediol) of at least 50 nmol/L. The target level depends on the population being supplemented, the assessed system, and the outcome. Several recent large randomized trials with oral vitamin D regimens varying between 2000 and 100,000 IU/month and mostly conducted in vitamin D-replete and healthy individuals have failed to detect any efficacy of these approaches for the prevention of fracture and falls. Considering the well-recognized major musculoskeletal disorders associated with severe vitamin D deficiency and taking into account a possible biphasic effects of vitamin D on fracture and fall risks, an European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group convened, carefully reviewed, and analyzed the meta-analyses of randomized controlled trials on the effects of vitamin D on fracture risk, falls or osteoarthritis, and came to the conclusion that 1000 IU daily should be recommended in patients at increased risk of vitamin D deficiency. The group also addressed the identification of patients possibly benefitting from a vitamin D loading dose to achieve early 25-hydroxyvitamin D therapeutic level or from calcifediol administration.